{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Analyze tumor samples and leukemic blasts from patients entered on this study for the presence of ras, raf, or FLT3 (leukemia) mutations.","groups":[{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG000","title":"Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2"}],"populationDescription":"This data were not and will never be collected","reportingStatus":"POSTED","timeFrame":"1 week prior to enrollment","title":"Leukemia Mutations","type":"SECONDARY"}